Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0153470 (Spleen)
 4,015 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Multiple low doses of streptozotocin are known to induce immune-mediated insulin deficient diabetes and depression of immune reactivity. We show here that immune depression by streptozotocin is not general but that some parts of the immune system are stimulated. Spleen cells from streptozotocin-treated mice showed enhanced cytotoxicity against syngeneic islet cells and various tumour cells including insulinoma cells. Several cell types served as effector cells, including macrophages, asialo GM1+ and Lyt-2+ lymphocytes. The increased cytotoxic activity towards islet cells was mostly due to macrophages and to non-asialo GM1+ and non-Lyt-2+ lymphocytes. A higher activation state of macrophages in low dose streptozotocin-treated mice was demonstrated by measurements of superoxide anion release. We conclude that multiple low doses of streptozotocin stimulate 'natural cytotoxicity', i.e. the non-MHC restricted cytotoxic activity of macrophages, T cells and natural killer lymphocytes.
 ...
PMID:Low dose streptozotocin causes stimulation of the immune system and of anti-islet cytotoxicity in mice. 165 63

We previously reported that streptococcal preparation (OK-432), which is a TNF inducer, inhibits insulitis and development of autoimmune diabetes in nonobese diabetic (NOD) mice and Bio-Breeding (BB) rats, as animal models of insulin-dependent diabetes mellitus. We have recently shown that recombinant human (h)TNF-alpha also suppresses development of diabetes in NOD mice. In this study we have extended our observation on TNF to BB rats in order to see whether TNF generally inhibits autoimmune diabetes. A total of 5 x 10(4) U of rhTNF-alpha was administered i.p., twice a week to male and female BB rats from 4 to 27 wk of age. The cumulative incidence of diabetes by 27 wk of age in nontreated rats was 36.4% (8/22), whereas that in hTNF-alpha-treated rats was 0% (0/21) (p less than 0.001). The hTNF-alpha-treated rats did not lose body weight and maintained normal blood glucose concentrations. Immunologic and histologic examinations were performed at the end of the experiment. Spleen cell cytotoxicities for NK-sensitive YAC-1 and rat insulinoma (RINm5F) cells in hTNF-alpha-treated rats significantly decreased in comparison with nontreated and nondiabetic BB rats. Intensity of insulitis was also inhibited in hTNF-alpha-treated rats. Interestingly, a huge hepatomegaly and splenomegaly was found in two of the 21 hTNF-alpha-treated rats. The latter consisted of W3/13dull+ and W3/25dull+ cells, which did not exhibit cytotoxicity for either YAC-1 or RINm5F cells. These results indicate that the chronic and systemic administration of TNF has a regulatory role in autoimmune diabetes in BB rats as well as in NOD mice, and that these animals may have a defect in TNF-mediated immunoregulation.
 ...
PMID:Inhibition of type 1 diabetes in BB rats with recombinant human tumor necrosis factor-alpha. 238 63

Spleen cells from acutely diabetic (AD) and non-diabetic but diabetes prone (DP) BB/Wor rats lysed insulinoma target cells to a significantly greater degree than did diabetes resistant (DR) cells as determined using a 51Cr release cytotoxicity assay. There were no differences between the AD and DP groups. Lysis was not target cell specific, since somatostatin secreting RIN 14B cells, Wistar Furth leukemia cells designated LW12, PC12 cells and NK sensitive YAC-1 cells were also lysed. Lysis of all target cells was significantly reduced by pretreatment of the effector lymphocytes with antiserum to NK cells (anti-asialo GM1) and complement suggesting that NK cells mediated destruction of these cells. These data demonstrate a generalized increase in non-specific NK cell activity in BB/Wor rats. Since NK cells have been shown to mediate antibody dependent cell mediated cytotoxicity (ADCC), splenic lymphoid cells from AD rats were tested for their ability to lyse insulinoma target cells in the presence of diabetic rat sera which were demonstrated to contain islet cell surface antibodies. Three different ADCC protocols were tested but in each case the addition of serum dilutions from AD rats reduced the lysis of insulinoma cells by AD spleen cells in a dose dependent manner. This inhibition was also demonstrated when sera and effector cells from control rats were used. As a positive control, DR spleen cells were incubated with 51Cr labelled target cells that were untreated or pre-treated with anti-rat class 1 antibody (OX18). Pre-treatment of the target cells resulted in a marked increase in their subsequent lysis.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:In vitro natural killer cell activity in the spontaneously diabetic BB/Wor rat: effects of serum on lysis of insulinoma cells. 285 69

A 37-year-old woman with a history of syncope was hospitalized with a diagnosis of hypoglycemia due to insulinoma. Computed tomography (CT) and magnetic resonance imaging revealed an enhanced solid mass, 1.5 cm in diameter, at the tail of the pancreas. Angiography via the splenic artery revealed a hypervascular mass. Because the tumor was located deep in the pancreatic parenchyma, laparoscopic distal pancreatectomy was performed. The pancreas was exposed by dissecting the greater omentum, and the tumor was located by intraoperative ultrasonography. After division of the splenic artery, the pancreas, main pancreatic duct, and splenic vein were transected with an endoscopic linear stapler. The pancreatic pedicle was divided at the splenic hilum to preserve the spleen. The postoperative course was uneventful except for the appearance of splenic infarction on a CT scan 2 weeks after surgery but without any overt symptoms. Spleen-preserving laparoscopic distal pancreatectomy by division of splenic vessels is a feasible treatment option for benign pancreatic disease.
 ...
PMID:Spleen-preserving laparoscopic distal pancreatectomy after division of the splenic vessels. 1524 71